Trial Profile
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Nimorazole (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms DAHANCA 30
- 12 Apr 2021 Planned number of patients changed from 1262 to 1252.
- 12 Apr 2021 Planned End Date changed from 1 Dec 2019 to 1 Dec 2023.
- 12 Apr 2021 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2023.